A PLACEBO-CONTROLLED TRIAL OF ICAM-1 ANTISENSE OLIGONUCLEOTIDE IN THETREATMENT OF CROHNS-DISEASE

Background & Aims: Intercellular adhesion molecule 1 (ICAM-1) plays an important role in the trafficking and activation of leukocytes and is up-regulated in inflamed mucosa in Crohn's disease. ISIS 2302 is an a ntisense phosphorothioate oligodeoxynucleotide that inhibits ICAM-1 ex pression. The aim of this study was to obtain preliminary assessment o f tolerability, pharmacology, and efficacy of ISIS 2302 in Crohn's dis ease. Methods: Twenty patients with active, steroid-treated Crohn's di sease were randomized (3:1, ISIS 2302 to placebo) to receive over 26 d ays 13 intravenous infusions of ISIS 2302 (0.5, 1, or 2 mg/kg) or sali ne placebo in a double-blinded study. The patients were followed up fo r 6 months. Results: At the end of treatment, 47% (7 of 15) of ISIS 23 02-treated and 20% (1 of 5) of the placebo-treated patients were in re mission (Crohn's Disease Activity Index [CDAI] < 150). At the end of m onth 6, 5 of these 7 ISIS 2302-treated remitters were still in remissi on, and a 6th patient had a CDAI of 156. Corticosteroid usage was sign ificantly lower (P = 0.0001) in the ISIS 2302-treated patients. These findings were corroborated by significant increases in beta(7) and alp ha(d) bearing CD3+ peripheral blood lymphocytes and by decreases in in testinal mucosal ICAM-1 expression during the treatment period. Conclu sions: ISIS 2302 seems to be a well-tolerated and promising therapy fo r steroid-treated Crohn's disease.